Latest news at the ROI Laboratory
Pieter Roelofs received a travel grant from the René Vogels Stichting
Pieter Roelofs, PhD candidate at the Radiotherapy & OncoImmunology laboratory, Dept. of Radiation Oncology, was awarded a 3500 EUR travel grant from the René Vogels Stichting. He received the award in order to perform a work visit to prof. Reuben Harris’ lab at theUniversity of Minnesota, Minneapolis, MN, USA. Pieter’s work is focused on the role of the DNA cytosine deaminase APOBEC3B in the development of therapy resistance in breast cancer. During his 14-months stay in Minneapolis as part of his KWF-funded project, he will investigate why this anti-viral enzyme is deregulated in a large proportion of breast tumors, leading to increased mutations and subsequent therapy resistance.
Early Career Investigator Award for Eva-Leonne Göttgens
Eva-Leonne Göttgens, PhD student at the Radiotherapy and OncoImmunology laboratory (ROI), has received an Early Career Investigator Award during the annual meeting of the Association for Radiation Research 2018 in Belfast. She presented the results of her collaboration with the Oxford Institute for Radiation Oncology and the ROI laboratory, which included new radiosensitising treatment strategies for head and neck squamous cell carcinomas.
Jeroen Slaats received the AIO award
At the Annual Dutch Tumor Immunology Meeting 2018, Jeroen Slaats, theme Cancer development and immune defense, received the AIO award for his presentation: “Tumor immune escape: Releasing the handcuffs from cytotoxic T cells”. The award includes a €500 travel grant.
Welcome at our LaboratoryThe experimental and clinical research program by the Radiotherapy & OncoImmunology Laboratory is aimed at:
Molecular Immunology programDendritic cells (DC) are the professional antigen presenting cells (APC) of our immune system. They are able to initiate immune responses against pathogens or tumors, but also have the capacity to prevent (auto)-immune responses harmful to the host. My research is centered around the molecular and functional analysis of DC in mouse and man. Applying different molecular approaches at the genomic and proteomic level a set of novel DC-antigens have been identified, including chemokines (DC-CK1, CXCL16), a novel multiple membrane spanning receptor (DC-STAMP), a transcription regulator (DC-SCRIPT). Knowledge regarding DC-immuno-biology is essential for the development and design of DC-based vaccines in mouse models as well as in clinical studies in cancer patients. More recently, regulatory T cells that are crucially involved in balancing the immune system are studied at the molecular and functional level as well as in immunotherapy of cancer.
VAMPAn important objective is the development of predictive profiles based on Vascular Architecture and Microenvironmental Parameters (VAMP). The ultimate goal is to provide a mechanistic basis for the optimization of treatments that combine radiotherapy with novel biological modifiers and for the development of patient selection strategies.
More information about the research program is in the section Research.